Welcome to our dedicated page for Annexon SEC filings (Ticker: ANNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Annexon SEC filings document a clinical-stage biopharmaceutical company developing C1q-targeted immunotherapies for neuroinflammatory and classical complement-mediated diseases. Its Form 8-K reports furnish operating results, portfolio progress, investor presentations, and strategic priority updates tied to programs such as vonaprument, tanruprubart, and ANX1502.
The company’s filings also cover proxy governance, annual meeting proposals, director elections, auditor ratification, executive compensation votes, board changes, and Nasdaq-listed common stock. Capital-structure disclosures include amendments to common stock purchase warrants and related rights of security holders.
Annexon, Inc. director William D. Waddill received a grant of stock options covering 65,000 shares of common stock at an exercise price of 4.70 per share. These options vest in full on the earlier of the first anniversary of June 11, 2026 or the next Annual Meeting following that date, as long as he continues serving as a director, and expire on June 11, 2036. Following this grant, he holds 65,000 options, reflecting routine equity-based director compensation rather than an open-market trade.
Annexon, Inc. director Muneer A. Satter received a grant of stock options covering 65,000 shares of common stock. The options have an exercise price of $4.70 per share and expire on June 11, 2036. They vest in full on the earlier of the first anniversary of June 11, 2026 or the next Annual Meeting after that date, contingent on his continued board service.
Annexon, Inc. director William A. Jones Jr. received a grant of stock options covering 65,000 shares of common stock. The options have an exercise price of $4.70 per share and expire on June 11, 2036.
The underlying shares vest and become exercisable in full on the earlier of the first anniversary of June 11, 2026 or the next Annual Meeting following that date, subject to his continuous service as a director until vesting.
Annexon, Inc. director Bettina M. Cockroft received a grant of stock options covering 65,000 shares of common stock. The options have an exercise price of $4.7000 per share and expire on June 11, 2036.
According to the terms, all 65,000 underlying shares vest and become exercisable as to 100% of the total on the earlier of the first anniversary of June 11, 2026 or the next Annual Meeting following that date, subject to her continuous service as a director until the vesting date.
Annexon, Inc. director Jung Choi received a grant of stock options covering 65,000 shares of common stock at an exercise price of $4.70 per share. These options vest in full on the earlier of the first anniversary of June 11, 2026 or the next Annual Meeting following that date, subject to continued board service, and expire on June 11, 2036. Following this award, Choi holds stock options for 65,000 underlying shares directly.
Annexon director William H. Carson received a grant of stock options covering 65,000 shares of Annexon common stock, with an exercise price of $4.70 per share. These options were awarded as compensation rather than bought in the open market.
The options vest and become fully exercisable as to 100% of the shares on the earlier of the first anniversary of June 11, 2026 or the next Annual Meeting following that date, as long as he continues serving as a director through vesting. The options expire on June 11, 2036, and following this grant he holds derivative rights over 65,000 shares.
Annexon, Inc. executive Ted Yednock exercised stock options to acquire additional common shares. On June 11, 2026, he exercised options for 30,646 shares of Annexon common stock at an exercise price of $1.8501 per share. After the transaction, he directly owned 184,807 common shares. The exercised options were fully vested and exercisable, and this filing shows a routine conversion of derivative awards into stock rather than an open-market purchase or sale.
Annexon, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 11, 2026. Stockholders elected Bettina M. Cockroft, M.D. with 101,594,745 votes for and 22,807,949 withheld, and Douglas Love, Esq. with 107,491,451 votes for and 16,911,243 withheld, with 17,818,815 broker non-votes for each.
Stockholders also approved additional proposals with strong support, including one receiving 142,016,122 votes for, 185,546 against and 19,841 abstentions, and another with 122,347,513 votes for, 1,986,387 against, 68,794 abstentions and 17,818,815 broker non-votes. A further proposal drew 129,051,256 votes for, 4,374,799 against and 8,795,454 abstentions.
Annexon, Inc. director Muneer A. Satter, through an affiliated investment entity, reported a large open-market purchase of the company’s common stock. On May 28, 2026, Alerce Medical Technology Partners, L.P. bought 613,497 shares at a price of $5.41 per share, with Satter having sole voting and dispositive power over these shares.
After this transaction, entities associated with Satter are shown as holding 10,342,134 shares in total, including 240,000 shares in the Muneer A. Satter Revocable Trust and additional shares in various trusts and partnerships. Satter disclaims beneficial ownership of many of these indirect holdings except to the extent of his pecuniary interest.
Annexon, Inc. ownership disclosure: Reporting Persons led by Biotechnology Value Fund entities report beneficial ownership positions in Annexon common stock as of the close of business on March 31, 2026. The filing lists individual holdings including 4,644,823 shares for BVF, 3,399,850 shares for BVF2 and 522,906 shares for Trading Fund OS.
The filing states an aggregate holding of 8,698,173 shares attributable through related entities and managed accounts, representing approximately 5.4% for certain reporting persons based on 160,474,333 shares outstanding plus 2,027,384 shares issued on March 27, 2026 upon exercise of pre-funded warrants.